Compare Adaptive Biotechnologies Corp (ADPT) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Skyworks Solutions Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.21 (market cap $3.33B), while Skyworks Solutions Inc trades at $59.09 (market cap $8.99B). The key difference: Skyworks Solutions Inc is far larger — about 2.7× Adaptive Biotechnologies Corp's market cap, and Skyworks Solutions Inc pays a 4.75% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SWKS | |
|---|---|---|
Market Cap | $3.33B | $8.99B |
Sector | Health | Technology |
52-Week High | $22.37 | $83.40 |
52-Week Low | $10.24 | $52.50 |
Enterprise Value | $3.19B | $8.76B |
Dividend Yield | — | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Skyworks Solutions (SWKS) trades at $59.76, down 4.48% on the day, with a bearish technical signal despite recent earnings beats. The company shows declining revenue and net income margins over recent years, though profitability metrics like gross margin remain solid at 41.08%. Recent news highlights product launches in EV and AI infrastructure alongside ongoing legal investigations into corporate governance.
The outlook is mixed: strong analyst buy consensus (60%) and a $72.56 price target suggest upside, but declining cash flow and revenue trends pose risks. Investment opportunity lies in market diversification and new tech segments, balanced against margin pressure and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
